EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)

Safety, pharmacokinetics and efficacy of a subcutaneous recombinant FVIII (OCTA101) in adult patients with severe haemophilia A

Toshko Lissitchkov iD, Martina Jansen, Johann Bichler, Sigurd Knaub

Haemophilia · 2024

DOI: 10.1111/hae.14898 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Haemophilia, 2024. Verfasst von Toshko Lissitchkov und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Clinical Hematology, Specialised Hospital for Active Treatment of Haematological Diseases, Sofia, Bulgaria. Hauptthemen laut MEDLINE: Hemophilia A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Regular, prophylactic intravenous (i.v.) FVIII can be challenging for some patients with haemophilia A. Subcutaneous (s.c.) FVIII administration could provide an alternative treatment option with greater convenience and without the complications associated with venous access.

Aim

To assess the safety, pharmacokinetics (PK), bioavailability and efficacy of s.c. OCTA101, a recombinant FVIII with a recombinant von Willebrand factor fragment dimer.

Methods

This was a single‐centre, prospective, open‐label, phase I/II study (NCT04046848). Previously treated male patients (≥18 years) with severe haemophilia A were eligible for the study. The primary objective of the study was to assess the safety (including immunogenicity) of OCTA101. Secondary objectives included assessments of PK, bioavailability, and the efficacy of prophylaxis.

Results

Thirty patients were treated with OCTA101. FVIII inhibitors developed in five (16.7%) patients during daily prophylaxis with 40–60 IU/kg (three cases) and 12.5 IU/kg (two cases) OCTA101. The trial was therefore terminated. OCTA101 had a 2.5‐fold longer terminal half‐life compared with i.v. rFVIII, and bioavailability was 16.6%. Efficacy data at study termination indicated that daily prophylaxis with 40–60 IU/kg OCTA101 was efficacious in the absence of FVIII inhibitors.

Conclusions

Despite promising PK and efficacy results, the trial was terminated due to the incidence of FVIII inhibitors. The occurrence of inhibitors at two dose levels suggests that their development may be related to the subcutaneous route of administration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AAdultHumansMaleProspective StudiesFactor VIIIvon Willebrand FactorAdministration, Intravenous

Stichwörter der Autor:innen

factor VIIIhaemophilia Aimmunogenicitysubcutaneous injection

Substanzen

Factor VIIIvon Willebrand Factor

Autor:innen und Institutionen

  • Clinic of Clinical Hematology, Specialised Hospital for Active Treatment of Haematological Diseases, Sofia, Bulgaria.
  • Disorders of Haemostasis, Octapharma Pharmazeutika Produktionsgesellschaft m.b.H., Vienna, Austria.
  • Disorders of Haemostasis, Octapharma AG, Lachen, Switzerland.

ORCID-Profile: Toshko Lissitchkov

Zitieren

APA

Lissitchkov, T., Jansen, M., Bichler, J., & Knaub, S. (2024). Safety, pharmacokinetics and efficacy of a subcutaneous recombinant FVIII (OCTA101) in adult patients with severe haemophilia A. Haemophilia. https://doi.org/10.1111/hae.14898

Vancouver

Lissitchkov T, Jansen M, Bichler J, Knaub S. Safety, pharmacokinetics and efficacy of a subcutaneous recombinant FVIII (OCTA101) in adult patients with severe haemophilia A. Haemophilia. 2024. doi:10.1111/hae.14898

BibTeX
@article{Lissitchkov2024,
  author = {Lissitchkov, Toshko and Jansen, Martina and Bichler, Johann and Knaub, Sigurd},
  title = {Safety, pharmacokinetics and efficacy of a subcutaneous recombinant FVIII (OCTA101) in adult patients with severe haemophilia A},
  journal = {Haemophilia},
  year = {2024},
  doi = {10.1111/hae.14898}
}
Kostenlos starten →